BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hrynchak I, Santos L, Falcão A, Gomes CM, Abrunhosa AJ. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies. IJMS 2021;22:10745. [DOI: 10.3390/ijms221910745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Martiniova L, Zielinski RJ, Lin M, Depalatis L, Ravizzini GC. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment. Cancer J 2022;28:446-453. [DOI: 10.1097/ppo.0000000000000625] [Reference Citation Analysis]
2 Lou H, Cao X. Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun (Lond) 2022. [PMID: 35822503 DOI: 10.1002/cac2.12330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lucas LM, Cullum RL, Markham JA, Woggerman JN, Dwivedi V, Mohamedelhassan RH, Cook LJ, Kelley CM, Knerr EL, Kaufmann DP, Jacobi MA, Taylor DC, Rael CC, Waits DS, Ghosh TM, Halanych KM, Gupta RB, Riese DJ. ERBB4 Mutant Alleles May Drive BRAF WT Melanomas.. [DOI: 10.1101/2022.06.21.22276707] [Reference Citation Analysis]
4 Lucas L, Cullum R, Dwivedi V, Markham J, Woggerman J, Kelley C, Knerr E, Cook L, Lucas H, Waits D, Ghosh T, Halanych K, Gupta R, Riese D. ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines.. [DOI: 10.1101/2022.06.20.22276663] [Reference Citation Analysis]
5 Dewulf J, Hrynchak I, Geudens S, Pintelon I, Vangestel C, Sereno J, van Dam PA, Abrunhosa AJ, Elvas F, Van den Wyngaert T. Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments. Pharmaceutics 2022;14:939. [DOI: 10.3390/pharmaceutics14050939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mayoral-Peña K, González Peña OI, Orrantia Clark AM, Flores-Vallejo RDC, Oza G, Sharma A, De Donato M. Biorecognition Engineering Technologies for Cancer Diagnosis: A Systematic Literature Review of Non-Conventional and Plausible Sensor Development Methods. Cancers (Basel) 2022;14:1867. [PMID: 35454775 DOI: 10.3390/cancers14081867] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fagbadebo FO, Kaiser PD, Zittlau K, Bartlick N, Wagner TR, Froehlich T, Jarjour G, Nueske S, Scholz A, Traenkle B, Macek B, Rothbauer U. A Nanobody-Based Toolset to Monitor and Modify the Mitochondrial GTPase Miro1. Front Mol Biosci 2022;9:835302. [DOI: 10.3389/fmolb.2022.835302] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Fagbadebo FO, Kaiser PD, Zittlau K, Bartlick N, Wagner TR, Froehlich T, Jarjour G, Nueske S, Scholz A, Traenkle B, Macek B, Rothbauer U. A nanobody-based toolset to monitor and modify the mitochondrial GTPase Miro1.. [DOI: 10.1101/2021.12.10.472061] [Reference Citation Analysis]